Emerging Trends in Phytochemical Nanomedicines for Lung Inflammation and Fibrosis Management
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202504927 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Dhanya M Shetty und 4 weiteren Autor:innen. Beteiligte Einrichtung: Polymer Nanobiomaterial Research Laboratory, Smart Materials and Devices Division, Yenepoya Research Centre, Yenepoya (Deemed to Be University), Mang…. Hauptthemen laut MEDLINE: Phytochemicals, Nanomedicine, Pulmonary Fibrosis, Pneumonia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 270 Literaturangaben. Gefördert von: Indian Council of Medical Research, Govt. of India, Investigator-Initiated Research Proposals for small extramural grants, Anusandhan National Research Foundation, Govt. of India.
Abstract (Originalsprache)
Lung inflammation, injury, and fibrosis are interconnected facets of respiratory health. Damage to the inherent lung architecture and tissue scarring resulting from excessive extracellular matrix deposition are the most important characteristics of lung injury and fibrosis. Although the current treatment strategy like Pirfenidone and Nintedanib, is effective in slowing the disease progression, they do not offer a complete cure. To suppress inflammation and pulmonary fibrosis progression, a variety of phytochemical drugs (Polyphenols, alkaloids, terpenoids, and carotenoids) have been investigated in the last decade. The bare administration of phytochemical drugs results in lower efficacy due to their low bioavailability, non‐specific release, and inadequate absorption in the lungs. With recent advancements in nanotechnology‐based drug delivery systems, researchers are highlighting the advantages of phytochemical drug delivery through a nanomedicine approach, with enhanced lung targetability and efficacy. In this review, the role of phytochemical drugs and the current status of phytochemical delivery using various nanocarriers (Polymeric, lipid, inclusion complexes, metal‐organic frameworks, hybrid, and lung targetable nanocarriers) for treating lung inflammation and fibrosis are presented.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Polymer Nanobiomaterial Research Laboratory, Smart Materials and Devices Division, Yenepoya Research Centre, Yenepoya (Deemed to Be University), Mangalore, India.
- Division of Cell and Molecular Biology, Yenepoya Research Centre, Yenepoya (Deemed to Be University), Mangalore, India.
- NanoLife Innovations Laboratory, Smart Materials and Devices Division, Yenepoya Research Centre, Yenepoya (Deemed to Be University), Mangalore, Karnataka, India.
ORCID-Profile: Dhanya M Shetty, Akarsha Balnadupete, Yashodhar P Bhandary, Saji Uthaman, Renjith P Johnson
Förderung
- Indian Council of Medical Research, Govt. of India
- Investigator-Initiated Research Proposals for small extramural grants
- Anusandhan National Research Foundation, Govt. of India
Zitieren
APA
Shetty, D. M., Balnadupete, A., Bhandary, Y. P., Uthaman, S., & Johnson, R. P. (2026). Emerging Trends in Phytochemical Nanomedicines for Lung Inflammation and Fibrosis Management. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202504927
Vancouver
Shetty DM, Balnadupete A, Bhandary YP, Uthaman S, Johnson RP. Emerging Trends in Phytochemical Nanomedicines for Lung Inflammation and Fibrosis Management. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202504927
BibTeX
@article{Shetty2026,
author = {Shetty, Dhanya M and Balnadupete, Akarsha and Bhandary, Yashodhar P and Uthaman, Saji and Johnson, Renjith P},
title = {Emerging Trends in Phytochemical Nanomedicines for Lung Inflammation and Fibrosis Management},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202504927}
}
EUVIMED